Difference between revisions of "Hand-foot syndrome (palmar-plantar erythrodysesthesia) management"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") |
Warner-admin (talk | contribs) m (Text replacement - "7 PubMed" to "7/ PubMed") |
||
| (10 intermediate revisions by 3 users not shown) | |||
| Line 19: | Line 19: | ||
==References== | ==References== | ||
| − | # Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40. [http://www.ejoncologynursing.com/article/S1462-3889%2804 | + | # Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40. [http://www.ejoncologynursing.com/article/S1462-3889%2804)00054-7 link to original article] [http://www.roche.com.mx/fmfiles/re756001/wp/AttachedFile_04470.pdf PDF of paper at Roche.com] [https://pubmed.ncbi.nlm.nih.gov/15341880/ PubMed] |
| − | # Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008 Feb;108(2):332-5. [https:// | + | # Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008 Feb;108(2):332-5. [https://doi.org/10.1016/j.ygyno.2007.10.021 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18083217/ PubMed] |
| − | # Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13(9):1001-11. Epub 2008 Sep 8. [ | + | # Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13(9):1001-11. Epub 2008 Sep 8. [https://doi.org/10.1634/theoncologist.2008-0131 link to original article] [https://pubmed.ncbi.nlm.nih.gov/18779536/ PubMed] |
# Lacouture, ME. Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome. ASCO Post. December 15, 2012, Volume 3, Issue 18. [http://www.ascopost.com/issues/december-15-2012/prevention-and-treatment-of-multikinase-inhibitor%E2%80%93induced-hand-foot-syndrome.aspx link to original article] | # Lacouture, ME. Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome. ASCO Post. December 15, 2012, Volume 3, Issue 18. [http://www.ascopost.com/issues/december-15-2012/prevention-and-treatment-of-multikinase-inhibitor%E2%80%93induced-hand-foot-syndrome.aspx link to original article] | ||
# [http://www.cancer.net/all-about-cancer/treating-cancer/managing-side-effects/hand-foot-syndrome-or-palmar-plantar-erythrodysesthesia Management/treatment of Hand-Foot Syndrome or Palmar-Plantar Erythrodysesthesia (Cancer.net)] | # [http://www.cancer.net/all-about-cancer/treating-cancer/managing-side-effects/hand-foot-syndrome-or-palmar-plantar-erythrodysesthesia Management/treatment of Hand-Foot Syndrome or Palmar-Plantar Erythrodysesthesia (Cancer.net)] | ||
| − | # [ | + | # [https://chemocare.com/chemotherapy/side-effects/handfoot-syndrome.aspx Patient education about hand-foot syndrome (Chemocare.com)] |
# [http://www.uptodate.com/contents/cutaneous-complications-of-conventional-chemotherapy-agents Cutaneous complications of conventional chemotherapy agents (uptodate.com)] | # [http://www.uptodate.com/contents/cutaneous-complications-of-conventional-chemotherapy-agents Cutaneous complications of conventional chemotherapy agents (uptodate.com)] | ||
# [http://www.uptodate.com/contents/cutaneous-complications-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy (uptodate.com)] | # [http://www.uptodate.com/contents/cutaneous-complications-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy (uptodate.com)] | ||
| Line 30: | Line 30: | ||
[[Category:General reference pages]] | [[Category:General reference pages]] | ||
| + | [[Category:Supportive oncology]] | ||
Latest revision as of 14:01, 4 May 2023
Associated with use of
- Aldesleukin (Proleukin)
- Capecitabine (Xeloda)
- Cytarabine (Ara-C)
- Doxorubicin (Adriamycin)
- Pegylated liposomal doxorubicin (Doxil)
- Floxuridine (FUDR)
- Fluorouracil (5-FU)
- Idarubicin (Idamycin)
- Ixabepilone (Ixempra)
- Lapatinib (Tykerb)
- Pazopanib (Votrient)
- Sorafenib (Nexavar)
- Sunitinib (Sutent)
- Vemurafenib (Zelboraf)
Also known as
Acral erythema, Burgdorf's reaction, hand-foot skin reaction, hand-to-foot syndrome, PPE, toxic erythema of the palms and soles
References
- Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40. link to original article PDF of paper at Roche.com PubMed
- Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008 Feb;108(2):332-5. link to original article PubMed
- Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008 Sep;13(9):1001-11. Epub 2008 Sep 8. link to original article PubMed
- Lacouture, ME. Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome. ASCO Post. December 15, 2012, Volume 3, Issue 18. link to original article
- Management/treatment of Hand-Foot Syndrome or Palmar-Plantar Erythrodysesthesia (Cancer.net)
- Patient education about hand-foot syndrome (Chemocare.com)
- Cutaneous complications of conventional chemotherapy agents (uptodate.com)
- Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy (uptodate.com)
- Prevention and management of hand-foot syndromes (Oncologynurseadvisor.com)